Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30509771

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2019 Jan
First author
Mamounas EP

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Jan;20(1):8-9. doi: 10.1016/S1470-2045(18)30663-6.
    note
    Source null
    related pmid
    30509770
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2019 Jan;20(1):e10. doi: 10.1016/S1470-2045(18)30926-4.
    note
    Source null
    related pmid
    30614468
    relationship
    Erratum in

Authors and identifiers

  1. name
    Mamounas EP
    type
    Author
  2. name
    Bandos H
    type
    Author
  3. name
    Lembersky BC
    type
    Author
  4. name
    Jeong JH
    type
    Author
  5. name
    Geyer CE Jr
    type
    Author
  6. name
    Rastogi P
    type
    Author
  7. name
    Fehrenbacher L
    type
    Author
  8. name
    Graham ML
    type
    Author
  9. name
    Chia SK
    type
    Author
  10. name
    Brufsky AM
    type
    Author
  11. name
    Walshe JM
    type
    Author
  12. name
    Soori GS
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Mamounas EP
    type
    Author
  2. name
    Bandos H
    type
    Author
  3. name
    Lembersky BC
    type
    Author
  4. name
    Jeong JH
    type
    Author
  5. name
    Geyer CE Jr
    type
    Author
  6. name
    Rastogi P
    type
    Author
  7. name
    Fehrenbacher L
    type
    Author
  8. name
    Graham ML
    type
    Author
  9. name
    Chia SK
    type
    Author
  10. name
    Brufsky AM
    type
    Author
  11. name
    Walshe JM
    type
    Author
  12. name
    Soori GS
    type
    Author
bibliography ids
  1. nci-bib-16fdeb1bde36ff50579d1899
book metadata
content sha256
68d0862dd3004312caeb209fdf88615bf581a897c0f81b27f828a748eed594d7
document type
citation
dois
  1. 10.1016/S1470-2045(18)30621-1
electronic publication date
display
2018 Nov 30
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30509771
immutable id
pubmed:30509771@68d0862dd3004312caeb209fdf88615bf581a897c0f81b27f828a748eed594d7
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
88-99
volume
20
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Jan;20(1):8-9. doi: 10.1016/S1470-2045(18)30663-6.
    note
    Source null
    related pmid
    30509770
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2019 Jan;20(1):e10. doi: 10.1016/S1470-2045(18)30926-4.
    note
    Source null
    related pmid
    30614468
    relationship
    Erratum in
outcomes validated
false
pmid
30509771
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
94008f4ecf8f147d16378ebd81bba716ed2f7bad4ac3db5f06844ae7bf9b1156
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2019 Jan
precision
month
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30509771/
title
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice